这是描述信息
搜索
这是描述信息
这是描述信息
Check category
All categories
Online customer service
Customer service hotline
Service time:
-
Customer service group:
在线客服

The SFDA remind attention double phosphonic acid salt, drug safety issues

Information

Recently, the national adverse drug reaction monitoring center stage 37 "bulletin of adverse drug reactions information bulletin double phosphonic acid salt of serious adverse drug reactions.

Double phosphonic acid salt drugs mainly used in the treatment of osteoporosis and bone metastases of malignancy and the treatment of the disease such as hypercalcemia. By the end of February 2011, national adverse drug reaction monitoring center received double phosphonic acid salt drug related report 1072 cases of adverse reactions.

The state food and drug administration recommended production enterprise timely perfect product manuals; Strengthen the propaganda, drug safety comprehensive inform security information in detail; Implement active surveillance, to collect information about varieties of adverse reactions, according to different varieties of different risk management plan, the greatest degree of the patient's medication security

 

 

TypeInfo: Industry news

Keywords for the information:

广东彼迪药业有限公司版权所有 © 2015 彼迪药业有限公司Copyright   中企动力提供网站建设  粤ICP备06032258号